Myasthenia Gravis
A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
Subtype terms (3)
More specific conditions that are subtypes of Myasthenia Gravis in the MeSH hierarchy.
- Lambert-Eaton Myasthenic Syndrome
10 drugs (8 approved, 2 experimental)
- Myasthenia Gravis, Autoimmune, Experimental
- Myasthenia Gravis, Neonatal
Drugs by status
Approved for this indication (11)
Phase 4 trials (6)
Phase 3 trials (24)
Phase 2 trials (26)
- cfz533
- naltrexone
- carmustine
- belimumab
- tak-079
- tirasemtiv
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- ondansetron
- cd19 car-t cells
- allogeneic bone marrow
- etoposide
- cytarabine
- apraclonidine
- melphalan
- autologous hematopoietic stem cells
- rvt-1401
- alxn1830
- Vemircopan
- baffr-car t cells
- caba-201
- cnp-106
- nmd670
- kyv-101
- dnth103
- im-101
Phase 1 trials (22)
- methylprednisolone
- tofacitinib
- Filgrastim
- oxaloacetate
- cyclophosphamide
- abatacept
- mesna
- fludarabine
- sargramostim
- ciltacabtagene autoleucel
- cc-97540
- gc012f
- bcma/cd19 dual-target car-t
- cd19 car-nk cells
- equecabtagene autoleucel
- emb-06
- lcar-aio cells
- musk-caart
- ucar-t cells
- cd20/bcma-directed car-t cells
- universal bcma car-t
- sys6020
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (28)
- CSL Behring
- UCB
- Roche
- Astellas
- Alexion
- Catalyst Pharmaceuticals, Inc.
- CuraVac
- Ra Pharmaceuticals
- National Institute of Neurological Disorders and Stroke (NINDS)
- Duke University
- Kanazawa University
- University of Miami
- University of Rochester
- University of Alberta
- Leiden University
- Food and Drug Administration
- Karolinska Institute
- Sun Yat-Sen University
- Mitsubishi Tanabe
- State University of New York, Buffalo
- University of Alabama, Birmingham
- George Washington University
- Carlo Besta Neurological Institute
- Aepodia
- Aspreva Pharmaceuticals
- University of Antwerp
- Viela Bio
- argenx
Organization Involved with Phase 2 Indications (22)
- Takeda
- Genentech
- Novartis
- GlaxoSmithKline
- RemeGen
- Cytokinetics
- National Cancer Institute (NCI)
- University of Washington
- Hoosier Cancer Research Network
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Kansas
- Yale University
- University of Vermont
- Fudan University
- Peking University
- Momenta Pharmaceuticals
- Humboldt University
- IQVIA
- Cartesian Therapeutics
- Immunovant Sciences GmbH
- Harbour BioMed Co. Ltd.
- DAS-MG, Inc
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (4)